Systemic Lupus Erythematosus | Disease Landscape & Forecast | G7 | 2025

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly variable between patients. GlaxoSmithKline’s Benlysta (2011) was the first drug to launch for SLE in the G7 in more than 50 years, but its modest efficacy is a deterrent to uptake. AstraZeneca’s Saphnelo (anifrolumab) was approved in 2021-2022 in the G7 for nonrenal SLE, and GlaxoSmithKline’s Benlysta and Aurinia’s Lupkynis (voclosporin) have been approved for adult patients with active lupus nephritis (LN). Several therapies in development for moderate to severe SLE without active renal disease and/or LN (i.e., anifrolumab, dapirolizumab pegol, voclosporin, obinutuzumab, litifilimab, ianalumab, deucravacitinib, telitacicept, and upadacitinib) are expected to fulfill the high unmet need associated with this condition. In this report, we provide detailed analysis of current medical practice, key unmet needs, and new developments in the SLE space, along with an analysis of the opportunities and obstacles facing emerging agents.

Questions answered

• How large is the treatable SLE population, and how will diagnosis / drug-treatment rates change over time?

• What is the current state of SLE treatment? What are interviewed experts’ insights into current treatments? What are the key unmet needs in SLE?

• What are KOLs’ perceptions of key emerging therapies, and where do they see these agents fitting into the treatment algorithm?

• What are the drivers and constraints in the SLE market, and how will the market evolve over the forecast period?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan

Primary research: Country-specific interviews with thought-leading rheumatologists and nephrologists; survey data collected for this and other Clarivate research

Epidemiology: Diagnosed prevalence of SLE by country and subpopulation (nonrenal SLE and LN)

Population segments in the market forecast: Total population, nonrenal SLE population, and renal SLE (LN) population

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.

• Quantify market potential for your pipeline assets and those of your competitors.

• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.

• Gauge the commercial outlook and impact of key market events.